Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
LSE:FAB
Price:
3.75 GBX
-1.32%
Market Closed
Updated:
Apr 20, 2024
Section:
Relative Value
The Relative Value of one
FAB
stock under the Base Case scenario is
11.03
GBX.
Compared to the current market price of 3.75 GBX,
Fusion Antibodies PLC
is
Undervalued by 66%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
FAB
Relative Value
Base Case
11.03
GBX
Undervaluation 66%
Valuation Multiples
Multiples Across Competitors
FAB Competitors Multiples
Fusion Antibodies PLC Competitors
Fusion Antibodies PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
Fusion Antibodies PLC
LSE:FAB
|
3.6m GBP | 2.3 | -1.3 | -1.1 | -1 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
210.2B USD | 4.9 | 35.1 | 21.8 | 31.9 | |
| US |
|
Danaher Corp
NYSE:DHR
|
173.7B USD | 7.3 | 36.6 | 24.8 | 35 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
41.3B USD | 2.8 | 30.4 | 16.6 | 25.6 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.6T KRW | 15 | 64.8 | 34.2 | 49.2 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
36.2B CHF | 5.4 | 55.3 | 19 | 27.9 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
39B USD | 5.8 | 31.5 | 25.2 | 30.3 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
27.7B USD | 9.4 | 46.7 | 31.9 | 38.2 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | 6.8 | 32.6 | 22.9 | 25.4 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
23.7B USD | 2.9 | 38.7 | 16.5 | 25.8 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.5B EUR | 6.7 | 59.7 | 31 | 46.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
